SYVN1-provoked RASA1 ubiquitination drives pulmonary inflammation in COPD via RAS/PI3K/Akt activation
Background
Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory lung disease characterized by persistent airflow limitation. Current therapies often fall short in effectively managing the underlying chronic inflammation and disease progression. Understanding the molecular mechanisms driving this inflammation is crucial for developing novel therapeutic strategies. Ras p21 protein activator 1 (RASA1) is a GTPase-activating protein that regulates RAS signaling, a pathway implicated in cell proliferation and inflammation. This study investigates RASA1's role and its regulation in COPD pathogenesis.
Study Design
Researchers enrolled COPD patients and age/sex-matched controls to analyze pulmonary RASA1 expression. They also utilized a cigarette smoke (CS)-evoked COPD mouse model and cigarette smoke extract (CSE)-exposed BEAS-2B human bronchial epithelial cells. Key methods included assessing RASA1 protein expression, measuring inflammatory cytokines, and evaluating RAS/PI3K/Akt pathway activation. Genetic deletion of SYVN1 was performed in CSE-exposed BEAS-2B cells to investigate its mechanistic role in inflammation and RAS/PI3K/Akt signaling.
Results
Pulmonary RASA1 expression was reduced in COPD patients compared to controls, progressively decreasing with disease severity. Correlative analysis revealed pulmonary RASA1 was positively associated with pulmonary function parameters and inversely correlated with inflammatory cytokines among COPD patients. RASA1 protein expression was also downregulated in lung tissues of CS-evoked COPD mice and CSE-exposed BEAS-2B cells. The RAS/PI3K/Akt signaling pathway was activated in lung tissues from COPD patients and mice, as well as in BEAS-2B cells after CSE treatment. A negative correlation was observed between SYVN1 and RASA1 in COPD patient lung tissues. Mechanistically, CSE exposure enhanced RASA1 proteasome degradation through elevating E3 ubiquitin ligase SYVN1. CS exposure facilitated inflammatory cytokine production via activating RAS/PI3K/Akt signaling.
Genetic deletion of
SYVN1alleviatedCSE-provoked inflammatory response via inhibitingRAS/PI3K/Aktsignaling in BEAS-2B cells.
Key Findings
- Pulmonary
RASA1expression was reduced in COPD patients and correlated with disease severity. RASA1expression was positively associated with pulmonary function and inversely correlated with inflammatory cytokines in COPD.E3 ubiquitin ligase SYVN1enhancedRASA1proteasome degradation uponCSEexposure.RAS/PI3K/Aktsignaling was activated in COPD patient lungs, mouse models, andCSE-exposed cells.- Genetic deletion of
SYVN1alleviatedCSE-provoked inflammation by inhibitingRAS/PI3K/Aktsignaling.
Why It Matters
This research identifies a novel mechanism where SYVN1-mediated RASA1 degradation contributes to COPD inflammation, suggesting a potential new therapeutic target. Modulating SYVN1 activity or stabilizing RASA1 could offer a strategy to dampen chronic inflammation in COPD patients. While promising, these findings are primarily from preclinical models and human correlative data. Further research is needed to develop specific SYVN1 inhibitors or RASA1 activators, and to validate their efficacy and safety in larger animal models and eventually human clinical trials. This mechanism could inform future drug development for COPD beyond current bronchodilator and corticosteroid approaches.
copd
inflammation
rasa1
syvn1
ras-pi3k-akt
ubiquitination